(Q33359823)

26 July 2017

Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma (English)

1 reference

intrahepatic cholangiocarcinoma

26 July 2017

0 references

1 reference

1 reference

Myung Ah Lee

1

1 reference

26 July 2017

In Sook Woo

2

1 reference

26 July 2017

Jin-Hyoung Kang

3

1 reference

26 July 2017

Young Seon Hong

4

1 reference

26 July 2017

Kyung Shik Lee

5

1 reference

26 July 2017

28 February 2004

1 reference

Journal of Cancer Research and Clinical Oncology

26 July 2017

1 reference

26 July 2017

130

1 reference

26 July 2017

6

1 reference

26 July 2017

346-350

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-003-0534-7

26 July 2017

0 references

cites work

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine

1 reference

12 December 2020

Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.

1 reference

12 December 2020

Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas

1 reference

12 December 2020

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

1 reference

12 December 2020

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

1 reference

12 December 2020

Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma.A study of 57 autopsy-proven cases

1 reference

12 December 2020

Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer

1 reference

12 December 2020

Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience

1 reference

12 December 2020

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

1 reference

12 December 2020

Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes

1 reference

12 December 2020

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

1 reference

12 December 2020

Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.

1 reference

12 December 2020

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

12 December 2020

Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas

1 reference

12 December 2020

Chemosensitivity in primary liver cancers: evaluation of the correlation between chemosensitivity and clinicopathological factors

1 reference

12 December 2020

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

12 December 2020

Primary liver cancer in Japan. Sixth report. The Liver Cancer Study Group of Japan

1 reference

12 December 2020

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

12 December 2020

10.1007/S00432-003-0534-7

Identifiers

DOI

1 reference

26 July 2017

1 reference